VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have received an average rating of “Reduce” from the five research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $0.95.

Several brokerages have recently commented on VTGN. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd.

Institutional Trading of VistaGen Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in VistaGen Therapeutics during the fourth quarter worth about $25,000. Cubist Systematic Strategies LLC purchased a new stake in VistaGen Therapeutics during the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in VistaGen Therapeutics during the third quarter worth about $39,000. Seven Fleet Capital Management LP purchased a new stake in VistaGen Therapeutics during the fourth quarter worth about $42,000. Finally, Tudor Investment Corp ET AL purchased a new stake in VistaGen Therapeutics during the fourth quarter worth about $50,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Price Performance

Shares of VTGN stock opened at $0.54 on Wednesday. The firm has a 50-day moving average of $0.60 and a 200-day moving average of $1.12. The company has a market cap of $21.31 million, a P/E ratio of -0.28 and a beta of 0.31. VistaGen Therapeutics has a one year low of $0.43 and a one year high of $5.14.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.